Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

| Patient: Patient, | Example |
| :--- | :--- |
| DOB | $12 / 31 / 1973$ |
| Sex: | Male |
| Patient Identifiers: | $01234567890 A B C D, 012345$ |
| Visit Number (FIN): | $01234567890 A B C D$ |
| Collection Date: | $01 / 01 / 201712: 34$ |

## Alpha Fetoprotein, CSF (Tumor Marker)

ARUP test code 0020729
Alpha Fetoprotein, CSF (Tumor Marker)


#### Abstract

$64 \mathrm{ng} / \mathrm{mL} \quad \mathrm{H} \quad$ (Ref Interval: 0-1) INTERPRETIVE INFORMATION: AFP, CSF (TUMOR MARKER) The Beckman coulter Access DXI AFP method is used. Results obtained with different assay methods or kits cannot be used interchangeably. AFP is a valuable aid in the management of nonseminomatous testicular cancer patients, when used in conjunction with information available from the clinical evaluation and other diagnostic procedures. Increased AFP concentrations have also been observed in ataxia telangiectasia, hereditary tyrosinemia, primary hepatocellular carcinoma, teratocarcinoma, gastrointestinal tract cancers with and without liver metastases, and in benign hepatic conditions such as acute viral hepatitis, chronic active hepatitis, and cirrhosis. The result cannot be interpreted as absolute evidence of the presence or absence of malignant disease. The result is not interpretable as a tumor marker in pregnant females. This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.


| VERIFIED/REPORTED DATES |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
| Procedure | Accession | Collected | Received | Verified/Reported |
| Alpha Fetoprotein, CSF (Tumor Marker) | 22-137-400794 | 5/17/2022 10:42:00 AM | 5/19/2022 12:12:41 AM | 5/19/2022 2:44:00 AM |

## END OF CHART

## H=High, L=Low, *=Abnorma1, C=Critical

